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Abstract
Background: Myasthenia gravis (MG) is a rare autoimmune disease mainly mediated by autoantibodies against the
acetylcholine receptor (AChR) at the neuromuscular junction. The thymus is the effector organ, and its removal
alleviates the symptoms of the disease. In the early-onset form of MG, the thymus displays functional and
morphological abnormalities such as B cell infiltration leading to follicular hyperplasia, and the production of AChR
antibodies. Type-I interferon (IFN-I), especially IFN-β, is the orchestrator of thymic changes observed in MG. As Dicer
and miR-29 subtypes play a role in modulating the IFN-I signalization in mouse thymus, we investigated their
expression in MG thymus.
Methods: The expression of DICER and miR-29 subtypes were thoroughly investigated by RT-PCR in human control and
MG thymuses, and in thymic epithelial cells (TECs). Using miR-29a/b-1-deficient mice, with lower miR-29a/b-1 expression,
we investigated their susceptibility to experimental autoimmune MG (EAMG) as compared to wild-type mice.
Results: DICER mRNA and all miR-29 subtypes were down-regulated in the thymus of MG patients and DICER expression
was correlated with the lower expression of miR-29a-3p. A decreased expression of miR-29 subtypes was similarly
observed in MG TECs; a decrease also induced in TECs upon IFN-β treatment. We demonstrated that miR-29a/b-1-
deficient mice were more susceptible to EAMG without higher levels of anti-AChR IgG subtypes. In the thymus, if no B
cell infiltration was observed, an increased expression of Ifn-β associated with Baff expression and the differentiation of
Th17 cells associated with increased expression of Il-6, Il-17a and Il-21 and decreased Tgf-β1 mRNA were demonstrated in
miR-29a/b-1-deficient EAMG mice.
Conclusions: It is not clear if the decreased expression of miR-29 subtypes in human MG is a consequence or a causative
factor of thymic inflammation. However, our results from the EAMG mouse model indicated that a reduction in miR-29a/
b1 may contribute to the pathophysiological process involved in MG by favoring the increased expression of IFN-β and
the emergence of pro-inflammatory Th17 cells.
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Introduction
MG is a neuromuscular disease characterized by invalidat-
ing muscle weaknesses. It is caused by autoantibodies tar-
geting components of the neuromuscular junction, such as
the acetylcholine receptor (AChR) [1]. In early-onset MG,
the thymus is the effector organ and its removal alleviates
the symptoms of the disease. The MG thymus displays
functional and morphological abnormalities characterized
by abnormal B cell infiltration leading to follicular hyperpla-
sia and the production of anti-AChR antibodies [1]. These
data indicate that disordered thymic processes underlie
MG; however, the molecular regulators of this dysfunction
remain to be elucidated. A thymic overexpression of inter-
feron (IFN)-β and IFN-I-induced genes is observed in MG,
even long after disease onset, and IFN-β seems to be the
main orchestrator of thymic changes [2–4]. Besides, a
causative role of IFN-I is supported by a mouse model
where injections of Poly(I:C) induce thymic changes that
lead to an anti-AChR response [3, 4].
Papadopoulou et al. demonstrated that miRNAs are
essential to protect thymic architecture. Using condi-
tional knock-out mice for Dicer in thymic epithelial cells
(TECs, Foxn1Cre Dicerfl/fl), they observed a premature
involution and the appearance of epithelial voids with
dense foci of B cells. Besides, Dicer-deficient mice are
hypersensitive to Poly(I:C) in line with increased expres-
sion of Ifnar1 in TECs. This latter effect is mediated by
the miR-29a/b-1 cluster, as miR-29a targets Ifnar1 and
increases the sensitivity to Poly(I:C) due to an increased
expression of Ifnar1 in TECs [5].
These observations suggest a link between miR-29a
and the IFN-I signature observed in MG thymus. Conse-
quently, we investigated the expression of DICER and
miR-29 subtypes in the thymus of MG patients and in-
vestigated the sensitivity of miR-29a/b-1-deficient mice
to experimental autoimmune MG (EAMG).
Methods
Human thymic samples
Thymic biopsies from early-onset MG patients (n = 12,
15–35 years old) were collected after thymectomy and con-
trol thymic biopsies (n = 6, 15–33 years old) were collected
from donors undergoing cardiovascular surgery at the Ma-
rie Lannelongue Surgical Center (Le Plessis-Robinson,
France). The degree of thymic follicular hyperplasia in MG
patients was assessed by pathologists (high degree of hyper-
plasia (MH patients (n = 6)) with 3 or more germinal cen-
ters per section vs. low degree of hyperplasia (ML patients
(n = 6)) with 2 or less germinal centers per section). MG
patients were only treated with cholinesterase inhibitors
and had no other known diseases including thymoma; all
their characteristics are detailed in Table 1. All the studies
on thymuses were approved by a local ethics committee
(CPP, authorization number ID RCB 2010-A00250-39) and
informed consent forms have been collected.
Primary human TECs were cultured from infant thymus
collected from donors undergoing cardiovascular surgery,
and correspond mainly to medullary TECs as previously
described [6]. TECs were seeded (1.4 × 105 cells/cm2) in
RPMI-5% horse serum for 24 hours. Next, TECs were
treated with IFN-β 1000 UI/ml (11415, R&D Systems,
Lille, France) in RPMI-0.5% horse serum for 24 h.
Animals
Thymic miR-29a/b-1-deficient mice on the B6 back-
ground were designed as previously described [5]. They
Table 1 Characteristics of patients whose thymus were used for RT-PCR experiments














MG1 F 15 Low 13 III b No Yes 3.45
MG2 F 23 Low 7 II a No Yes 2118.7
MG3 F 29 Low 7 I a No NS 83.7
MG4 F 35 Low 24 IV a No Yes 11.1
MG5 F 20 Low 6 II a No Yes > 100
MG6 F 32 Low 6 II b No Yes 17.3
MG7 F 30 High 2 IV a No NS > 100
MG8 F 30 High 14 I No NS 3180.2
MG9 F 25 High 3 II a No Yes 3.21
MG10 F 28 High 4 II a No Yes 60.38
MG11 F 28 High 36 III a No Yes 9.7
MG12 F 22 High 2 III a No Yes 264
(1) Degree of thymic hyperplasia: low hyperplasia (with 2 or fewer GCs per section) or high hyperplasia (with 3 or more GCs per section). (2) Clinical classification
according to the Myasthenia Gravis Foundation of America (MGFA)
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were decontaminated upon arrival by embryo transfer in
C57BL/6j mice purchased at Janvier Labs (Saint-Berthe-
vin, France). Afterward, mice were bred and host in a
specific pathogen-free animal care facility (Centre d’Ex-
périmentation Fonctionelle, Sorbonne Université, Paris,
France) according to European and French ethics agree-
ments (n° 2569.01).
RT-PCR for miRNAs on human thymic biopsies
Total RNA was extracted from human thymic biopsies
using the mirVana miRNA Isolation Kit. Biopsies were
first lysed in the lysis/binding buffer provided in the mir-
Vana kit using the FastPrep FP120 instrument (Qbiogen,
Illkirch, France). RNA integrity was assessed on a Bioa-
nalyzer 2100 (Agilent Technologies, Les Ulis, France).
miRNAs were retro-transcribed from total RNA using
the TaqMan MicroRNA Reverse Transcription Kit and
following the Custom RT Pool protocol (ThermoFisher
Scientific, Villebon-sur-Yvette, France). Briefly, RT
primers were pooled with RNA samples so that the miR-
NAs expression could be assessed in a unique sample.
qPCR reactions were carried out using the TaqMan Uni-
versal Master Mix II, no UNG (Life Technologies) on a
LightCycler 480 (Roche, Meylan, France). PCR settings
were as follows: 1 cycle of polymerase activation and de-
naturation at 95 °C for 10 min, 45 cycles of amplification
at 95 °C for 15 s and 60 °C for 1 min. miRNA expression
was normalized to 28S. Primers used for qPCR are listed
in Table 2.
RT-PCR for mRNAs
Total RNA from human thymus was obtained as
described above. Total RNA from mouse thymus or
from TEC cultures were extracted in TRIzol (Thermo-
Fisher Scientific) using the FastPrep FP120 instrument
(Qbiogen, Illkirch, France) for thymic biopsies. RNA (1
μg) was reverse-transcribed for 1 h at 42 °C using AMV
(Ref 10109118001, Roche Life Science, Meylan, France)
with oligo-dT (ThermoFisher Scientific). PCR reactions
were carried out with the LightCycler 480 SYBR Green
Master Mix on the LightCycler® 480 System (Roche). All
samples were normalized to 28S or GAPDH. The primer
sequences (Eurogentec, Angers, France) are listed in
Table 3.
Experimental autoimmune myasthenia gravis (EAMG)
Six to 8-week-old C57BL/6 male and female mice were
used as inbred miR-29 a/b-1 heterozygous (HET), WT
siblings on the C57BL/6 background, and additional
C57BL/6j WT mice from Janvier Labs. Male and female
mice were combined in the analyses, with no sex-based
differences observable in the EAMG model [7]. The
extraction of Torpedo Californica AChR (T-AChR) was
led as previously described [8]. T-AChR was emulsified
with an equal volume of Complete Freund’s adjuvant
(CFA; F5881, ThermoFisher Scientific) supplemented
with heat-inactivated Mycobacterium tuberculosis (10
mg/ml, H37RA, BD Difco, Villepinte, France). Mice were
subcutaneously injected (200 μl/mouse, 30 μg AChR) at
several sites (hind foot-pads, tail base and in the back).
Control mice were injected similarly with CFA emulsion
devoid of T-AChR. After 4 weeks, mice were immunized
a second time with T-AChR emulsified in CFA only at
the tail base and in the back.
The global clinical score was graded from 0 to 9 by tak-
ing into account the weight evolution, muscle strength,
and the inverted grid test. Each of these measures was
graded on 3, as described by Weiss et al. with minor mod-
ifications as follows [8]. The grip test measurements were
done after a 5-min run in a treadmill. Grip test values
were normalized on the weight of the animals since exper-
iments were performed on female and male mice. For
each mouse, the weight and grip test measures were com-
pared to those obtained before the immunization, and a
percentage representing the loss/gain of weight or of
muscle strength along the experiment was determined.
The grading on 3 was then made as detailed by Weiss
et al. [8]. For the inverted grid test, mice were first tired by
gently dragging them across a grid 20 times. Immediately
after, the grid was inverted and held steadily for 1′30 ′′.
During this time-lapse, mice were carefully observed to
detect any signs of abnormal behavior. Mice were consid-
ered sick when they reached a global clinical score of 2.
Mice reaching a global clinical score of 9 were euthanized.
Table 2 List of TaqMan microRNA assays used for custom RT pool and qPCR on miRNAs
Assay ID miRNA name miRBase ID Sequence
002112 hsa-miR-29a-3p MIMAT0000086 UAGCACCAUCUGAAAUCGGUUA
002447 hsa-miR-29a-5p MIMAT0004503 ACUGAUUUCUUUUGGUGUUCAG
000413 hsa-miR-29b-3p MIMAT0000100 UAGCACCAUUUGAAAUCAGUGUU
002165 hsa-miR-29b-1-5p MIMAT0004514 GCUGGUUUCAUAUGGUGGUUUAGA
002166 hsa-miR-29b-2-5p MIMAT0004515 CUGGUUUCACAUGGUGGCUUAG
000587 hsa-miR-29c-3p MIMAT0000681 UAGCACCAUUUGAAAUCGGUUA
001818 hsa-miR-29c-5p MIMAT0004673 UGACCGAUUUCUCCUGGUGUUC
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ELISA for anti-AChR antibodies
ELISA experiments were carried out on serum samples
collected at sacrifice (day 43). 96-well plates were coated
with 0.5 μg/mL of T-AChR diluted in 10 mM NaHCO3
buffer, pH 9.6, overnight at 4 °C. Wells were blocked
with PBS 10% fetal calf serum for 2h30 at 37°C. Samples
were diluted in PBS 0.2% BSA (1:100 000) and incubated
at 37 °C for 1 h and 30 min. One hundred microliters of
biotinylated rabbit anti-mouse IgG (1/10000, E0413,
Dako, Courtaboeuf, France) or biotinylated anti-mouse
IgG subtypes were added for 1 h and 30 min at 37 °C
(anti-IgG2b 1/250 (553393, BD Biosciences, Le Pont de
Claix, France); anti-IgG2c (1/5000, SA5-10235, Thermo-
Fisher Scientific) or anti IgG1 (1/100; 553441, BD Biosci-
ences). Samples were incubated 30 min with 100 μL of
streptavidin–horseradish peroxidase (diluted at 1:10 000)
(S911, ThermoFisher Scientific). Tetramethylbenzidine
was used for color development, and the optical density
at 450 nm was measured with the SPARK 10 M micro-
plate reader (TECAN Life Sciences, Grödig, Austria).
Between each step, wells were washed 4 times with 200
μl of PBS 0.05% Tween 20.
Detection of relative affinity of anti-AChR IgG antibodies
The relative affinity of anti-AChR IgG antibodies was
determined based on the above ELISA method using a
potassium thiocyanate (KSCN) elution step [9]. Increas-
ing concentrations of KSCN in 0.1 M PBS (pH 6.0) for
15 min at room temperature before the biotinylated
rabbit anti-mouse IgG. KSCN concentrations ranging
from 1 to 8 M were tested. As anti-AChR antibodies
were totally removed at higher KSCN concentrations
than 4 M of KSCN. Concentrations below 4 M of KSCN
were used for linear regression in GraphPad and the
relative affinity corresponds to the molarity of KSCN
resulting in 50% of the absorbance obtained in the ab-
sence of KSCN.
Immunohistochemistry
Cryosections of thymic samples (7 μm) were fixed in ice-
cold acetone for 20 min and unspecific binding sites
blocked with 2% BSA. Sections were stained for medullary
thymic epithelial cells with a Keratin 5 polyclonal antibody
(Biolegend, Ozyme, Saint-Cyr-L’école, France) and a
donkey anti-rabbit IgG Alexa-Fluor-488 (ThermoFisher
Table 3 List of primers used for RT-PCR on mRNAs
Gene name Sens primer Antisens primer
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Scientific), while B cells were detected with a B220 biotinyl-
ated antibody (clone RA3-6B2, BD Biosciences) and strep-
tavidin Alexa-Fluor-594 (S11227, ThermoFisher Scientific).
Images were acquired with a ZeissAxio Observer Z1
Inverted Microscope. The number of B cells was counted
in 6–8 fields representative of each thymic section.
Statistical analysis
For 2-by-2 comparisons, the non-parametric Mann-
Whitney test was applied as specified in figure legends.
To analyze the mouse susceptibility to EAMG, the com-
parisons among the different mouse groups in kinetic
were performed using a two-way ANOVA with Bonfer-
roni adjustment for multiple comparisons. Correlation
analyses were performed using Spearman’s correlation
coefficient for non-Gaussian distributed variables, with a
p < 0.05 considered significant.
Results
Decreased expression of DICER correlates with reduced
miR-29a-3p expression in MG patients
To investigate the putative role of the DICER/miR-29/
IFN-I axis in MG, we analyzed the expression of DICER
mRNA, a key enzyme in miRNA biogenesis. We observed
a 4.6-fold decrease of expression in the thymus of MG pa-
tients, compared to healthy control thymus (Fig. 1a). Even
if the DICER mRNA expression seemed lower in patients
with a high degree of follicular hyperplasia (Fig. 1a), this
was independent of the abnormal presence of B cells in
the thymus. Indeed, no correlation between CD19 and
DICER mRNA expression was observed (Fig. 1b). To
assess the impact of reduced DICER expression on the
global miRNA profile, we analyzed published miRnome
data obtained from the same thymic biopsies [10]. Analyz-
ing the expression of 1733 mature thymic miRNAs in MG
patients as compared to controls, we observed almost an
equal repartition of up- and down-miRNAs, with 904 and
829 miRNAs with a fold change (FC) higher and lower
than 1, respectively (Fig. 1c). Despite no systematic impact
of reduced DICER expression on the global expression of
thymic miRNAs, we observed a significant correlation
between DICER mRNA and miR-29a-3p expression
(Fig. 1d). As Papdopoulou et al. demonstrated that
DICER deletion in TECs increased sensitivity to IFN-I
signalization and that miR-29a was the best candidate
to mediate this effect [5, 1]. This association of reduced
DICER and miR-29a expression in the MG thymus war-
ranted further investigation as a potential causative link.
The miR-29 family is downregulated in the thymus of MG
patients
The miR-29 subtypes are expressed by two genomic clus-
ters: the miR-29a cluster (miR-29a/b-1 on chromosome 1
in human and mice) and the miR-29c cluster (miR-29b-2/
c on chromosome 7 in human and chromosome 1 in
mice) [11]. Using miRnome data previously published
[10], we observed a significant decrease expression of all
the members of the miR-29 family (miR-29a-3p, miR-29c-
3p, miR-29b-2-5p*, miR-29b-3p, miR-29c-5p*, miR-29b-
1-5p* and miR-29a-5p*) in MG thymuses compared to
control thymuses (Fig. 2a). To validate these observations,
we analyzed by RT-PCR the expression of all miR-29 sub-
types. We observed that miR-29a-3p was the most
strongly expressed miR-29 thymic subtype (Fig. 2a, b), as
consistent with the data from the mouse thymus [5]. We
confirmed that all miR-29 miRNAs were significantly
downregulated in MG thymuses except the very low
expressed miR-29b-1-5p* (Fig. 2b). Detailed results are
showed for the three most highly expressed miRNAs,
miR-29a-3p, miR-29b-3p, and miR-29c-5p* (Figs. 2c, e, g).
The decreases were observed in all MG thymuses inde-
pendent of the degree of thymic hyperplasia. In addition,
ROC curve analyses demonstrated the high sensitivity and
Fig. 1 Altered DICER expression in human MG thymuses. a RT-PCR analysis for DICER mRNA in the thymus of non-MG adults (n = 6) and MG patients
(n = 12) with a low (orange dots) and high (red dots) degree of thymic hyperplasia. Data were normalized to the 28S. P values were assessed by the
Mann-Whitney test. b Correlation between DICER and CD19 mRNA expression in control (grey dots) and MG thymuses (orange and red dots) was
performed using Spearman’s correlation test, with a p < 0.05 considered significant. c Using data from a thymic miRnome study [10], the distribution
of FCs (fold changes) for 1733 mature miRNAs. Each FC was calculated by comparing the mean of raw intensity values for MG thymuses (n = 12) over
the one of non-MG adult control thymuses (n = 6). d Correlation between DICER mRNA and miR-29a-3p expression in control (grey dots) and MG
thymuses (orange and red dots) was performed using Spearman's correlation test, with a p < 0.05 considered significant
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Fig. 2 (See legend on next page.)
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specificity for these three miR-29 subtypes for discriminat-
ing MG patients from controls (Fig. 2d, f, h).
These data demonstrated that miR-29 subtypes were
all downregulated in the thymus of MG patients, poten-
tially leading to a higher expression of genes targeted by
miR-29 miRNAs.
miR-29 subtypes are downregulated in TECs from MG
patients
To determine the cellular source of miR-29 dysregula-
tion in the MG thymus, we analyzed the level of expres-
sion of the three main thymic miR-29 subtypes in TECs
derived from thymic explant cultures. We observed
decreased expression or downwards trends for each of
the three miR-29 subtypes tested (Fig. 3a). We also ana-
lyzed miR-29a-3p, miR-29b-3p, and miR-29c-5p* expres-
sion in thymocytes/lymphocytes freshly extracted from 5
MG and 5 control thymuses. miR-29a-3p and miR-29b-
3p were expressed at 4–7-fold lower levels in thymocytes
versus TECs from control donors, and miR-29c-5p* was
borderline undetectable in thymocytes. No decrease
expression of miR-29 subtypes was observed in thymo-
cytes from MG patients compared to non-MG controls
(data not shown), further supporting that the decreased
expression in TECs could reflect what was observed at
the whole thymus level. Nevertheless, the decrease in
TECs was less significant than in the whole MG thymus
probably as TECs were analyzed after 7 days in culture
conditions that are different than the inflammatory
thymic MG context.
Despite the decrease expression of the three miR-29
subtypes, no increased expression for IFNAR1 was
observed (Fig. 3b). This suggests that there might be a
threshold level for miR-29 to decrease IFNAR1 mRNA
expression in TECs. In addition, human IFNAR1 is not
listed as targeted by miR-29a according to the usual
sequence matching databases (miRanda, TargetScan, and
DIANA microT), and thus species differences clearly
exist. A link between miR-29 and the IFN-I pathway was
assessed through the exposure of TECs from healthy
donors to IFN-β, as IFN-β is known to be overexpressed
in the thymus of MG patients [3]. Through analyzing
(See figure on previous page.)
Fig. 2 Decreased expression of miR-29 subtypes in human MG thymuses. a miR-29 subtypes expression was assessed using data from a thymic
miRnome study [10]. Each point corresponds to the mean of raw intensity values for 6 non-MG adult control thymuses and 12 MG thymuses. p
value was assessed by the Wilcoxon test. b–h miR-29 subtypes expression was assessed by RT-PCR in 6 non-MG adult control thymuses and 12
MG thymuses. b Each point corresponds to the mean values for the controls and MG thymuses. p values were assessed by the Wilcoxon test. c,
e, g Detailed expression of miR-29a-3p, miR-29b-3p, and miR-29c-5p in control and MG thymuses with a low (orange dots) and high (red dots)
degree of thymic hyperplasia. Data were normalized to the 28S. p values were assessed by the Mann-Whitney test. d ,f ,h Analyses of the
sensitivity and specificity with ROC curves for miR-29a-3p, miR-29b-3p, and miR-29c-5p* in control and MG thymuses
Fig. 3 Altered expression of miR-29 subtypes in human TECs. a RT-PCR analyses of miR-29a-3p, miR-29b-3p, and miR-29c-5p* expressions in TECs
from non-MG thymuses (n = 12–16) compared to MG thymuses (n = 14–17). b RT-PCR analysis of IFNAR1 in TECs from non-MG adult thymuses
(n = 10) compared to MG thymuses (n = 11). Data were normalized to the 28S (c). TEC cultures from 6 different donors were stimulated for 24 h
with IFN-β and miR-29a-3p analyzed by RT-PCR. Data were normalized to the GAPDH. p values were assessed by the Mann-Whitney test for a and
b and by the Wilcoxon test for c
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the effect of IFN-β on miR-29a-3p, the most highly
expressed miR-29 subtype, we observed that IFN-β induced
a decreased expression of miR-29a-3p (Fig. 3c). The effect
of IFN-β on miR-29a-3p expression is independent of
DICER as IFN-β did not affect DICER mRNA expression
in TECs (data not shown). Together, these data indicate
that the down-regulation of miR-29 subtypes in the thymus
of MG patients could be due to a lower expression of these
miRNAs in TECs, potentially mediated in response to high
levels of IFN-β exposure in the MG thymus.
miR-29a/b-1 heterozygous mice display a higher
sensitivity to MG
The observation of reduced DICER and miR-29a
expression in MG patient thymuses suggests a potential
causative pathway for disease. Based on the known biology
of miR-29a, the reduced expression could elevate response
to IFN-I, escalating the disease process. Conversely, the
identified expression changes in patients could be correla-
tive, rather than causative. In order to test a potential
causative link, we turned to the mouse model. Mice
heterozygous for the deletion in the miR-29a/b-1 cluster
(HET mice) mimic the 2-fold expression decrease
observed in MG patients [5]. We, therefore, sought to
compare the response of HET and wild-type (WT) control
mice to the induction of MG, using the EAMG model.
Using a global clinical score, we observed that miR-
29a/b-1 HET mice were more susceptible to EAMG
induction compared to WT mice. HET mice developed
symptoms more rapidly than WT mice even before the
Fig. 4 Higher susceptibility to EAMG of miR-29a/b-1 heterozygous mice.C57BL/6 WT and miR-29a/b-1 HET mice were immunized with CFA/T-AChR or
just CFA (for a group of WT mice) at day 0 and boosted at day 30 (as indicated with arrows in a). Clinical evaluations were done at days 0, 14, 28, and
42. A global clinical score was calculated for each mouse taking into account the weight loss, the grip test, and the inverted grid test, as detailed in
the method section. a Mean of global clinical scores was calculated for each mouse group (±SEM) and showed in kinetic. Data were analyzed by the
two-way ANOVA test and p values determined with Bonferroni posttests. p values are indicated if significant with grey asterisks for WT/T-AChR and
HET/T-AChR as compared to WT/CFA, and with bleu asterisks for HET/T-AChR as compared to WT/T-AChR. b Global clinical scores were given for each
mice at the end of the experiment (day 42). c, d Anti-T-AChR antibodies were measured by ELISA and detected with anti-mouse IgG (c), IgG2b (d),
IgG2c (e), or IgG1 (f) antibodies. Relative affinity index of anti-AChR IgG antibodies was determined using KSCN thiocyanate as detailed in the methods
(g). b–g p values were assessed by the Mann-Whitney test. Male mice are represented with grey dots
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boost immunization (Fig. 4a). At the end of the experi-
ment, 92% of HET mice were sick (with a global clinical
score over 2) as compared to only 63% for the WT mice
(Fig. 4b). We measured the serum levels of anti-T-AChR
IgG and specifically anti-AChR IgG1, IgG2b, and IgG2c
(IgG2 isotypes acting via the complement in C57BL/6
mice). All mice immunized with T-AChR developed
anti-AChR antibodies that were not detected in CFA-
injected control mice. However, we did not observe any
differences between miR-29a/b-1 HET mice compared
to WT mice (Figs. 4c–f). We also measured the levels of
anti-mouse AChR IgG, IgG2b, and IgG2c by coating the
ELISA plates with a mouse AChR peptide but did not
detect any increased level of anti-mouse AChR anti-
bodies in miR-29a/b-1 HET mice (data not shown).
Consequently, the levels of anti-AChR antibodies did
not explain the higher clinical score observed in miR-
29a/b-1 HET mice. To characterize the properties of
anti-AChR antibodies from WT as compared to miR-
29a/b-1 HET mice, we measured the antibody affinity
but did not detect any difference between the two mouse
strains (Fig. 4g).
Upon induction of EAMG, HET mice exhibited strong
thymic involution (Fig. 5a) consistent with published re-
sults. A decrease in cellularity is observed in the thymus
of miR-29 KO mice from 9 weeks old but the proportion
of double-positive, double-negative, CD4, or CD8 thy-
mocytes are not affected [5]. Unlike the published work,
however, we did not detect an increase in CD19+ B cells
in the thymus of HET mice, by either immunohisto-
chemistry (Figs. 5b, c) or by RT-PCR (Fig. 5d). In
addition, no increases were detected for Cxcl13 or Ccl21
mRNAs (Figs. 5e, f), two chemokines involved in B cell
recruitment in MG thymus, or for Cxcr5 mRNA (Fig.
5g), Cxcl13 receptor essential for B recruitment [12, 13].
Baff mRNA expression was significantly upregulated in
the thymus of miR-29a/b-1 HET mice compared to WT
and CFA mice (Fig. 5h).
Regarding the IFN-I signature, no increased expression in
Ifnar1 or Ifnar2 mRNAs was observed in miR-29a/b-1
HET mice (Figs. 5i–j). However, in the thymus of miR-29a/
b-1 HET mice, Ifn-β mRNA was significantly increased
compared to WT mice (Fig. 5k) and Ifn-α2 mRNA was also
slightly increased but only compared to CFA mice (Fig. 5l).
Cytokines defining T cell subsets were also analyzed by RT-
PCR: Ifn-γ (expressed by Th1 cells), Il-4 (expressed by Th2
cells), Il-10 and Tgf-β1 (expressed by Treg cell), Il-17a and
Il-21 (expressed by Th17 cells), Il-6, Il-23 (inducing Th17
differentiation). No changes were observed for Ifn-γ,
Il-4, Il-10 (Fig. 5m, o) and a decrease was observed
for Tgf-β1 (Fig. 5p) in miR-29a/b-1 HET compared to
WT mice. However, we observed a clear increased ex-
pression of Il-17a and Il-21 in miR-29a/b-1 HET mice
as compared to WT mice (Fig. 5r, t, u) suggesting an
increase in Th17 cells. Accordingly, the expression of Il-6
known to favor Th17 differentiation was also increased in
the thymus of miR-29a/b-1 HET mice (Fig. 5r) but not
that of IL-23 (Fig. 5s).
Altogether, these results demonstrate that reduced
miR-29 can have a direct pathological impact on the
disease MG susceptibility. This is independent of thymic
B cell infiltration but could be associated with a stronger
Th17 signature.
Discussion
miRNAs are potent modulators of protein expression
and are therefore involved in many physiological and
pathophysiological processes. Specific miRNAs are
already known to be involved in thymic pathogenesis as-
sociated with MG [10, 14–16]. Here, we investigated the
implication of DICER and the miR-29 family in thymic
changes in early-onset MG.
We observed a significant decreased expression of
DICER in MG thymuses. Papadopoulou et al. showed
the importance of Dicer in mouse thymic architecture
by deleting Dicer specifically in TECs [5]. They observed
a premature thymic involution, the formation of epithe-
lial voids, and the presence of dense B cell foci. In early-
onset MG, the thymus is characterized by increased
presence of B cells and germinal center development [1].
However, here, we did not observe a correlation between
DICER expression and the degree of follicular thymic
hyperplasia or the expression of CD19 mRNA. The
decreased expression of DICER in the thymus of MG
patients did not seem as critical as the total deletion of
Dicer in TECs in mice, as it did not lead to a global de-
creased expression of thymic miRNAs. However, DICER
also possesses non-canonical, miRNA-independent roles
[17]. DICER protects cells from cytotoxic accumulation
of endogenous dsRNAs, such as Alu RNAs that can lead
to abnormal activation of damage-associated molecular
patterns (DAMPs) and subsequently sterile inflammation
associated with IFN-I signalization [18]. Cufi et al. dem-
onstrated that the injection of dsRNA to mice leads to
thymic changes in link with IFN-I signalization and
favors the development of a specific autoimmune reaction
against AChR [3].
We observed a significant correlation between DICER
expression and miR-29a in human MG thymuses. In
light of the pathological nature of IFN-I in MG [3, 4],
and the role of miR-29a in desensitizing the thymus to
IFN-I [5], this suggests a putative pathological pathway.
The proposed pathway between Dicer and IFN-I signal-
ing in the mouse is via miR-29a/b-1 regulation of Ifnar1
expression in TECs. Elevated Ifnar1 in TECs would
explain the increased sensitivity of miR-29a/b-1-deficient
mice to pathogen-related signals, as demonstrated with
the injection of Poly(I:C) [5]. Here, we observed that all
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Fig. 5 (See legend on next page.)
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miR-29 subtypes were downregulated in the thymus of
MG patients. This decreased expression was also observed
in TEC cultures deriving from MG thymuses and could
be in link with the inflammatory status of the MG thymus,
as we observed a decreased expression of miR-29a in
TECs upon IFN-β treatment. In multiple sclerosis pa-
tients, a downregulation of miR-29 family is also observed
in peripheral blood mononuclear cells upon IFN-β treat-
ment [19]. Besides, a decreased expression of miR-29a has
also been observed in other inflammatory conditions, such
as in fibroblasts in systemic sclerosis [20], in lung and
plasma in chronic obstructive pulmonary disease [21], in
renal tissues in IgA nephropathy [22], in peripheral blood
T cells in Hashimoto’s thyroiditis patients [23], and upon
bacterial infection in IFN-γ producing cells [24].
As miR-29 subtypes were downregulated by about 50%
in MG thymuses, we wondered if miR-29 HET mice
were more susceptible to EAMG and displayed thymic
changes as in the human disease. We demonstrated that
miR-29 HET mice were more susceptible to EAMG ac-
cording to the global clinical score. A decrease of thymic
miR-29 miRNAs could favor the emergence of autoreac-
tive T cells against α-AChR, as the absence of miR-29a/
b-1 cluster selectively affects the Aire-dependent tissues-
specific antigen expression in TECs [25]. Nevertheless,
this enhanced susceptibility to EAMG does not seem
due to a genetic increase in autoimmunity, as miR-29a/
b-1 KO are protected in the collagen-induced arthritis
(CIA) mouse model [26].
In our EAMG experiment, miR-29a/b-1 HET mice did
not display higher anti-AChR antibody titers and the affin-
ity of their anti-AChR antibodies was not altered either.
Similarly, in MG patients, the severity of the disease is not
correlated with the antibody titer [1], and it is correlated
with the degree of thymic follicular hyperplasia [27]. How-
ever, we did not observe increased B cell infiltration and
follicular hyperplasia in the thymus nor did we observe in-
creased expression of chemokines susceptible to induce B
cell recruitment. It should be noted that while the EAMG
model with WT C57BL/6 mice leads to the production of
anti-AChR antibodies and muscular symptoms as for MG
patients, this model does not show any of the thymic
abnormalities observed in the human disease [28]. In mice,
a strong combination of inflammation and CXCL13 over-
expression seems mandatory to initiate thymic B cell re-
cruitment [29, 8].
It was previously published that the regulation of ifnar1
expression by miR-29a was a likely molecular mediator
[5]. We did not observe an increased thymic expression of
Ifnar1 either because the decrease in miR-29a/b1 in
heterozygous mice was not sufficient or because mRNA
analyses were done in whole thymus and not in purified
TECs. Ifnar2 mRNA expression, that could also be tar-
geted by miR-29a (www.targetscan.org), was not altered
either. However, in our EAMG experiment, we showed
the overexpression of thymic IFN-β mRNA in miR-29a/b1
HET as compared to WT mice. In WT C57BL/6 mice, a
thymic increase in Ifn-β promotes the overexpression of
chemokines such as CXCL13 and CCL21 that favor B cell
recruitment [4]. It is possible that in heterozygous miR-29
mice the level of Ifn-β was not sufficient to trigger the
expression of these chemokines and a subsequent B cell
recruitment. It was nevertheless strongly associated with
the overexpression of Baff, and the differentiation of Th17
associated with increased expression of Il-6, Il-17a, and Il-
21 mRNA. BAFF expression in increased in MG thymus
[4]. BAFF is known to induce the expansion of activated B
cells and their survival but no increased number of B cells
was detected in EAMG WT and miR-29 HET mice.
Recent research works have also demonstrated that
BAFF can promote T cell activation, proliferation, and
differentiation, in particular for Th17 cells [30]. Zhou
et al. demonstrated that constitutive overexpression of
Baff in transgenic mice promotes the generation of Th17
cells and aggravates experimental autoimmune encephalo-
myelitis (EAE) [31]. A decrease in Tgf-β1 was also detected
in the thymus of miR-29-deficient mice in the EAMG
model. Tgf-β1 plays an important role in controlling auto-
immunity and abnormal inflammation by providing signals
limiting immune activation and in particular suppressing
Th17 cells expansion [32]. At low concentrations, Tgf-β1
synergizes with IL-6 and IL-21 favoring Th17 cell differenti-
ation [33]. In the human MG disease, a Th17 signature is
also observed in the thymus [34]. This Th17 signature
could explain that miR-29a/b1 HET were more severely
affected in the EAMG model.
(See figure on previous page.)
Fig. 5 Inflammatory thymic signature in miR-29a/b-1 heterozygous mice in the EAMG model C57BL/6 WT and miR-29a/b-1 HET mice were
immunized with CFA/T-AChR or just CFA (for a group of WT mice) at day 0 and boosted at day 30. Mice were sacrificed at day 43. Male mice are
represented with grey dots. a The weight of thymuses was normalized to mouse weight. b Representative picture of thymus labeling for cell
counting. Thymic sections were stained for TECs with a Keratin 5 antibody (green) and for B cells with a B220 antibody (red). c The number of B
cells was counted in 6–8 fields representative of thymic sections and each point corresponds to the mean for each mice. d–u RT-PCR analyses for
Cd19, Cxcl13, Ccl21, Cxcr5, Ifnar1, Ifnar2, Ifn-β, Ifn-α2, Il-6, Il-23, Il-17a, Il-21, Ifn-γ, Il-4, Il-10, and Tgf-β1 mRNA expression in mouse thymuses. Data
were normalized on GAPDH. p values were assessed by the Mann-Whitney test
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Conclusion
So far, most of thymic miRNAs described as dysregu-
lated in early-onset are associated with GC development,
such as miR-7, miR-24, miR-139, miR-143, miR-145,
miR-146, miR-150, miR-452, miR-548, or thymic inflam-
mation, such as miR-125b and miR-146 [16]. Here, we
showed that miR-29a/b1 seems also link to thymic
inflammation. In mouse, if a decrease of miR-29a/b1 can
optimized IFN-I signalization by modulating Ifnar1
mRNA expression in TECs [5], it could also lead to Ifn-β
mRNA expression in the context of EAMG, in addition
to other pro-inflammatory cytokines such as Il-6, Il-17a,
and Il-21. In the human thymus, a decreased expression
of miR-29a-3p was observed in MG patients and also in
TECs upon IFN-β treatment. Yet, it is not clear if the
decreased expression of miR-29 subtypes in MG is either
a consequence or a causative factor of the thymic
inflammation. Anyhow, our results indicated that a
reduction in miR-29 subtypes may contribute to the
pathophysiological process involved in MG by favoring
the emergence of pro-inflammatory Th17 cells.
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